ClinicalTrials.gg
Active, not recruitingNCT05567796REDEFINE 1Updated Sep 30, 2026

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

A Phase 3 interventional study of Cagrilintide and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 256 sites in 23 countries. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Updated Sep 30, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,400
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Planned enrollment
Largest of 36
3,400 · median 154
Started
2022
the only one that year
Phase 3
15 of 36
4 open now
Primary completion
2024-10
later than 0 of 14 live
Registered
10th of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one has the largest planned enrollment, is the only one that started in 2022, is one of 15 in phase 3, reaches primary completion later than 0 of the 14 other live ones, and was the 10th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms.

Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age above or equal to 18 years at the time of signing
  • (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m\^2) or b) BMI greater than or equal to 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

Exclusion criteria

Exclusion Criteria:

- Glycaemia related: a) (HbA1c) greater than or equal to 6.5 percent (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening b) History of type 1 or type 2 diabetes mellitus

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,400 participants (estimated)

Study arms

  • Experimental
    Cagrisema

    Participants will receive cagrilintide and semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Active comparator
    Cagrilintide

    Participants will receive cagrilintide s.c. and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks.

    Drug: Cagrilintide · Drug: Placebo semaglutide

  • Active comparator
    Semaglutide

    Participants will receive semaglutide s.c.and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks.

    Drug: Semaglutide · Drug: Placebo cagrilintide

  • Placebo comparator
    Placebo s.c.

    Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks.

    Drug: Placebo cagrilintide · Drug: Placebo semaglutide

Interventions

  • Cagrilintide will be administered subcutaneously.

  • Participants will recieve semaglutide subcutaneously.

  • DrugPlacebo cagrilintide

    Participants will receive placebo matched to cagrilintide.

  • DrugPlacebo semaglutide

    Participants will receive placebo matched to semaglutide.

06

What researchers measure

Primary outcomes

  1. CagriSema versus placebo: Relative change in body weight

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  2. CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction

    Measured as count of participants

    Time frame: From baseline (week 0) to end of treatment (week 68)

Secondary outcomes

  1. CagriSema versus placebo: Achievement of >= 20% weight reduction

    Measured as count of participant

    Time frame: From baseline (week 0) to end of treatment (week 68)

  2. CagriSema versus placebo: Achievement of >= 25% weight reduction

    Measured as count of participant

    Time frame: From baseline (week 0) to end of treatment (week 68)

  3. CagriSema versus placebo: Achievement of >= 30% weight reduction

    Measured as count of participant

    Time frame: From baseline (week 0) to end of treatment (week 68)

  4. CagriSema versus cagrilintide and CagriSema versus semaglutide: Relative change in body weight

    Measured as percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  5. CagriSema versus placebo: Relative change in body weight

    Measured as percentage (%)

    Time frame: From baseline (week 0) to week 8

  6. CagriSema versus placebo: Relative change in body weight

    Measured as percentage (%)

    Time frame: From baseline (week 0) to week 20

  7. CagriSema versus placebo: Change in waist circumference

    Measured in centimeters (cm)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  8. CagriSema versus placebo: Change in systolic blood pressure (SBP)

    Measured in millimeters of mercury (mmHg)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  9. CagriSema versus placebo: Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score

    Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  10. CagriSema versus placebo: Change in SF-v2 Health Survey Acute (SF-36 v2 Acute) Physical Functioning Score

    Measured as score points. The SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  11. CagriSema versus placebo, semaglutide and cagrilintide: Change in body weight

    Measured in kilograms (kg)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  12. CagriSema versus placebo, semalutide and cagrilintide: Change in body mass index (BMI)

    Measured in kilogram per square meter (kg/m\^2)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  13. CagriSema versus placebo, semaglutide and cagrilintide: Improvement in weight category

    Measured as count of participants. The categories are: BMI, underweight less than (\<) 18.5, normal weight 18.5 to \<25, overweight 25.0 to \<30, obesity class I 30 to \< 35, obesity class II 35 to \< 40, obesity class III \>40.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  14. CagriSema versus placebo: Change in Glycated Haemoglobin (HbA1c)

    Measured as percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  15. CagriSema versus placebo: Change in HbA1c

    Measured as millimoles per mole (mmol/mol).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  16. CagriSema versus placebo: Change in Fasting Plasma Glucose (FPG) (mmol/L).

    Measured as millimoles per liter (mmol/L).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  17. CagriSema versus placebo: Change in FPG (mg/dL)

    Measured as milligrams per deciliter (mg/dL).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  18. CagriSema versus placebo: Ratio to baseline in fasting serum insulin

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  19. CagriSema versus placebo: Change in Diastolic Blood Pressure (DBP)

    Measured in mmHg

    Time frame: From baseline (week 0) to end of treatment (week 68)

  20. CagriSema versus placebo: Ratio to baseline in total cholesterol

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  21. CagriSema versus placebo: Ratio to baseline in High-density lipoprotein (HDL) cholesterol

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  22. CagriSema versus placebo: Ratio to baseline in Low-density lipoprotein (LDL) cholesterol

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  23. CagriSema versus placebo: Ratio to baseline in Very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  24. CagriSema versus placebo: Ratio to baseline in Triglycerides

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  25. CagriSema versus placebo: Ratio to baseline in Free fatty acids

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  26. CagriSema versus semaglutide and cagrilintide: Change in waist circumference

    Measured in centimeters (cm)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  27. CagriSema versus semaglutide and cagrilintide: Change in SBP

    Measured in mmHg

    Time frame: From baseline (week 0) to end of treatment (week 68)

  28. CagriSema versus semaglutide and cagrilintide: Ratio to baseline in total cholesterol

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  29. CagriSema versus semaglutide and cagrilintide: Ratio to baseline in HDL

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  30. CagriSema versus semaglutide and cagrilintide: Ratio to baseline in LDL

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  31. CagriSema versus semaglutide and cagrilintide: Ratio to baseline in VLDL

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  32. CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Triglycerides

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  33. CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Free fatty acids

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  34. CagriSema versus placebo: Relative change in body weight (Measured in kilograms (kg))

    Measured in kilograms (kg).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  35. CagriSema versus placebo: Relative change in body weight (Measured in percentage (%))

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  36. CagriSema versus placebo: Absolute change in body weight (Measured in kilograms (kg))

    Measured in kilograms (kg).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  37. CagriSema versus placebo: Absolute change in body weight (Measured in percentage (%))

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  38. CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as kilograms (kg))

    Measured as kilograms (kg)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  39. CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as percentage (%))

    Measured as percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  40. CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as kilograms (kg))

    Measured as kilograms (kg)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  41. CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as percentage (%))

    Measured as percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  42. CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as percentage (%))

    Measured as percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  43. CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as %-points)

    Measured as %-points

    Time frame: From baseline (week 0) to end of treatment (week 68)

  44. CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as percentage (%))

    Measured as percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  45. CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as %-points)

    Measured as %-points

    Time frame: From baseline (week 0) to end of treatment (week 68)

  46. CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in kilograms (kg))

    Measured in kilograms (kg)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  47. CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in percentage (%))

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  48. CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in kilograms (kg))

    Measured in kilograms (kg)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  49. CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in percentage (%))

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  50. CagriSema versus placebo: Achievement of at least 14.6- point increase (yes/no) in IWQOL-Lite-CT Physical Function score

    Measured as count of participants. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  51. CagriSema versus placebo: Achievement of at least 3.7-point increase (yes/no) in SF-36v2 Physical Functioning score

    Measured as count of participants. The SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  52. CagriSema versus placebo: Change in IWQOL-Lite-CT - Physical Function Score

    Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  53. CagriSema versus placebo: Change in IWQOL-Lite-CT - Psychosocial Score

    Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  54. CagriSema versus placebo: Change in IWQOL-Lite-CT - Total Score

    Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  55. Change in Control of Eating (COEQ): Craving Control Score

    Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  56. Change in COEQ: Craving for Savoury food score

    Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  57. Change in COEQ: Hunger score

    Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  58. Change in COEQ: Craving for Sweets Score

    Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  59. Change in COEQ: Positive Mood score

    Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  60. Change in COEQ: Satiety score

    Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  61. CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Change in IWQOL-Lite-CT Physical Function score

    Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  62. CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite-CT Physical Function score

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  63. CagriSema versus placebo, semalutide and cagrilintide: Ratio to baseline C-reactive protein (CRP)

    Measured as ratio

    Time frame: From baseline (week 0) to end of treatment (week 68)

  64. Number of Treatment Emergent Adverse Events (TEAEs)

    Measured as count of events

    Time frame: From baseline (week 0) to end of study-main part (week 75)

  65. Number of Treatment Emergent Serious adverse events (TESAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study-main part (week 75)

07

Study locations

256 sites

Showing the first 100 of 256 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Verma S, Bottcher M, Brown P, Dicker D, Rubino D, Sbraccia P, Sharma AM, Smedegaard L, Sorrig R, Garvey WT. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. 2026 Feb;83(2):e26055. doi: 10.1161/HYPERTENSIONAHA.125.26055. Epub 2025 Dec 2. PubMed 41328546 ↗
  • Garvey WT, Bluher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietilainen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH; REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025 Aug 14;393(7):635-647. doi: 10.1056/NEJMoa2502081. Epub 2025 Jun 22. PubMed 40544433 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Oct 2024, 23 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 23 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 5, 2022
StartActual
Nov 1, 2022
Primary completionActual
Oct 30, 2024
CompletionEst.
Oct 19, 2026
Results delay requested
Oct 27, 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Gierach-Med · Bydgoszcz, Poland
Show 1 removed
  • Gierach-Med · Bygdoszcz, Poland
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    1 site added, 1 site removed
    Show site
    • Gierach-Med · Bydgoszcz, Poland
    Show 1 removed
    • Gierach-Med · Bygdoszcz, Poland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05567796
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Nov 1, 2022
Primary completion
Oct 30, 2024
Completion
Oct 19, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion